A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 1, 2004, Pages 16-24

  Ueda, Yasuji ^a   Yamagishi, Takehiro ^a   Samata, Kazunori ^a   Ikeya, Hisao ^a   Hirayama, Noriko ^a   Okazaki, Tadayasu ^a   Nishihara, Sumi ^a   Arai, Koshi ^a   Yamaguchi, Sachiko ^b   Shibuya, Masabumi ^b   Nakaike, Shiro ^a   Tanaka, Makoto ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Antitumor activity; Vascular endothelial cell; Vascular permeability; VEGF binding antagonist; VGA1102

Indexed keywords

5 [3 [4 (OCTADECYLOXY)PHENYL]PROPIONYLAMINO] 2,4' OXYDIBENZOIC ACID; ANTINEOPLASTIC AGENT; IODINE 125; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VGA 1102;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOPHOSPHORYLATION; BLOOD VESSEL PERMEABILITY; CELL LINE; CONTROLLED STUDY; DRUG ACTIVITY; EMBRYO; ENDOTHELIUM CELL; GUINEA PIG; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIFESPAN; LIVER CELL; LIVER SINUSOID; LUNG NON SMALL CELL CANCER; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR BINDING; SCREENING; STATISTICAL SIGNIFICANCE; TUMOR GROWTH;

ALKANES; ANGIOGENESIS INHIBITORS; ANIMALS; BENZOIC ACIDS; CAPILLARY PERMEABILITY; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CELL LINE; GUINEA PIGS; INFUSIONS, PARENTERAL; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR WEIGHT; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, WISTAR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3042803907     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0763-8     Document Type: Article

References (28)

1. Aviezer D, Cotton S., David M, Segev A, Khaselev N, Galili N, Gross Z, Yayon A (2000) Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis. Cancer Res 60:2973
2. Bae D, Gho Y, Yoon W, Chae C (2000) Arginine-rich antivascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis. J Biol Chem 275:13588
3. Binetruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, Plouet J, Derbin C, Perret G, Mazie JC (2000) Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 19:1525
4. Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527
5. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocrinol Rev 18:4
6. Fidler IJ, Ellis LM (1994) The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185
7. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27
8. Fong TAT, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99
9. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841
10. Kondo S, Asano M, Suzuki H (1993) Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Commun 194:1234
11. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TAT, Strawn LM, Sun L, Tnag C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington JM (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152
12. Luo JC, Yamaguchi S, Shinkai A, Shitara K, Shibuya M (1998) Significant expression of vascular endothelial growth factor/ vascular permeability factor in mouse ascites tumors. Cancer Res 58:2652
13. Luo JC, Toyoda M, Shibuya M (1998) Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 58:2594
14. Nakaike S, Yamagishi T, Nanaumi K, Otomo S, Tsukagoshi S (1992) Cell-killing activity and kinetic analysis of a novel antitumor compound NC-190, a benzo[a]phenazine derivative. Jpn J Cancer Res 83:402
15. Prewett MHJ, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59:5209
16. Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janic N (1998) 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273:20556
17. Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M (1996) Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ 7:213
18. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983
19. Shibuya M (1995) Role of VEGF-Flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 67:281
20. Shibuya M, Ito N, Claesson-Welsh L (1999) Structure and function of vascular endothelial growth factor receptor-1 and - 2. Curr Topics Microbiol Immunol 237:59
21. Tashiro T, Inaba M, Kobayashi T, Sakurai Y, Maruo K, Ohnishi Y, Ueyama Y, Nomura T (1989) Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses. Cancer Chemother Pharmacol 24:187
22. van Bruggen N, Thibodeaux H, Palmer JT, Lee WP, Fu L, Cairns B, Tumas D, Gerlai R, Williams SP, van Lookeren Campagne M, Ferrara N (1999) VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest 104:1613
23. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF (2000) ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 60:970
24. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hoffman F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F, Marme D (2000) PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178
25. Xu L, Yoneda J, Herrera C, Wood J, Killion JJ, Fidler IJ (2000) Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 16:445
26. Yamagishi T, Nakaike S, Ikeda T, Ikeya H, Otomo S (1996) A novel antitumor compound, NC-190, induces topoisomerase II-dependent DNA cleavage and DNA fragmentation. Cancer Chemother Pharmacol 38:29
27. Yamane A, Seetharam L, Yamaguchi S, Goto N, Takahashi T, Neufeld G, Shibuya M (1994) A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene 9:2683
28. Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ (2000) Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 6:957